223 related articles for article (PubMed ID: 21437082)
1. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
Gallwitz B
Diabetes Metab Syndr Obes; 2010 May; 3():117-24. PubMed ID: 21437082
[TBL] [Abstract][Full Text] [Related]
2. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.
Sharma MD
Ther Clin Risk Manag; 2010 May; 6():233-7. PubMed ID: 20526441
[TBL] [Abstract][Full Text] [Related]
3. Clinical overview of saxagliptin for Type 2 diabetes management.
Rosenstock J
Expert Rev Endocrinol Metab; 2010 Nov; 5(6):809-823. PubMed ID: 30780831
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
5. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
Konya H; Yano Y; Matsutani S; Tsunoda T; Ikawa T; Kusunoki Y; Matsuo T; Miuchi M; Katsuno T; Hamaguchi T; Miyagawa J; Namba M
Ther Clin Risk Manag; 2014; 10():547-58. PubMed ID: 25050065
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Boulton DW
Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Gilbert MP; Pratley RE
Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
[TBL] [Abstract][Full Text] [Related]
8. Saxagliptin for type 2 diabetes.
Chacra AR
Diabetes Metab Syndr Obes; 2010 Sep; 3():325-35. PubMed ID: 21437102
[TBL] [Abstract][Full Text] [Related]
9. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
Davidson JA
Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S27-37. PubMed ID: 21106865
[TBL] [Abstract][Full Text] [Related]
10. Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
Shubrook J; Colucci R; Guo A; Schwartz F
Clin Med Insights Endocrinol Diabetes; 2011; 4():1-12. PubMed ID: 22879789
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
12. Alogliptin: a new addition to the class of DPP-4 inhibitors.
Andukuri R; Drincic A; Rendell M
Diabetes Metab Syndr Obes; 2009 Jul; 2():117-26. PubMed ID: 21437125
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin.
Dhillon S; Weber J
Drugs; 2009 Oct; 69(15):2103-14. PubMed ID: 19791828
[TBL] [Abstract][Full Text] [Related]
14. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
17. DPP-4 Inhibition and the Path to Clinical Proof.
Ahrén B
Front Endocrinol (Lausanne); 2019; 10():376. PubMed ID: 31275243
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
[TBL] [Abstract][Full Text] [Related]
19. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
